Capricor Faces Securities Suit Over Dermamiocel Plan Changes

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a securities class action lawsuit alleging that the company misled investors about the regulatory status of its Dermamiocel Biologics License Application. The complaint, filed by Kaplan Fox & Kilsheimer LLP, covers a class period from December 17, 2025, to July 26, 2026. According to the filing, Capricor failed to disclose that it altered its pre-specified statistical analysis plan without prior FDA review or agreement.

The alleged misrepresentations came to light on July 27, 2026, when the FDA released briefing documents ahead of its AdCom meeting. The documents indicated that the final statistical analysis plan was not submitted to the FDA for review before the BLA submission. Following this disclosure, Capricor’s stock price declined by $12.70, or 64%, to close at $7 per share. Investors who acquired securities during the specified window are now encouraged to contact the firm before the September 28, 2026, lead plaintiff deadline.

Alleged Statistical Plan Irregularities

The core of the complaint centers on the integrity of Capricor’s statistical analysis plan (SAP) for Dermamiocel. The plaintiffs argue that the company made changes to the pre-specified SAP that were neither submitted to the FDA for review prior to the BLA submission nor discussed with the agency. Consequently, the final version of the plan was not agreed upon by the FDA. This lack of transparency is alleged to have deprived investors of material information regarding the regulatory hurdles facing the drug candidate.

The revelation occurred when the FDA published briefing documents before its Advisory Committee meeting on July 27, 2026. These documents detailed the discrepancies in the SAP, confirming that the version used for the application differed from what was previously presented. This disclosure triggered an immediate negative reaction in the market, as the implications for the drug’s approval pathway became clear.

Market Reaction and Legal Timeline

The market response to the FDA’s briefing documents was severe. Capricor shares dropped $12.70 on July 27, 2026, representing a 64% loss in value to a closing price of $7. The lawsuit seeks to recover losses incurred by investors who purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026. The firm notes that potential lead plaintiffs must file a motion with the court by September 28, 2026, to assume the role, though other class members can still seek recovery without this step.

Firm Background and Litigation History

Kaplan Fox & Kilsheimer LLP is the lead counsel in this matter. The firm, founded in 1956, specializes in complex securities and antitrust litigation. It has recovered over $10 billion for clients in recent years, including a $2.425 billion settlement for Bank of America shareholders and an $800 million recovery for the Arkansas Teacher Retirement System. The firm maintains offices in New York, Oakland, Los Angeles, Chicago, and New Jersey, and frequently represents institutional investors and public pension funds in high-stakes federal and state court actions.